Literature DB >> 28547157

Shikonin induces necroptosis by reactive oxygen species activation in nasopharyngeal carcinoma cell line CNE-2Z.

Zixuan Zhang1, Zhirui Zhang2, Qixiang Li2, Hao Jiao2, Dianlong Chong2, Xiaojin Sun2, Pei Zhang2, Qiang Huo3, Hao Liu4.   

Abstract

Shikonin, a natural small agent, has shown inhibitory effect in many kinds of cells, which increases intracellular reactive oxygen species (ROS) level and causes mitochondrial injury. In this study, shikonin showed good inhibitory effect on nasopharyngeal carcinoma CNE-2Z cells in vivo and vitro. The results presented here revealed that ROS levels increased markly after shikonin treated. The electron microscopy displays the change in ultrastructure of CNE-2Z cells after treatment for shikonin, which indicated that shikonin induced necroptosis. Shikonin-induced cell death was inhibited by a necroptosis inhibitor, necrostatin-1 (Nec-1), while the activity was unaffected by the caspase inhibitor z-VAD-fmk. Furthermore, we have demonstrated that the activation of receptor-interacting kinase (RIP) led to necroptosis. Meanwhile, shikonin also significantly inhibited tumor growth in a CNE-2Z xenograft mouse model. Taken together, shikonin induced CNE-2Z cells death by producing ROS as a necroptosis inducer. It could serve as a new therapeutic agent for treating CNE-2Z cells.

Entities:  

Keywords:  Nasopharyngeal carcinoma; Necroptosis; Reactive oxygen species; Shikonin

Mesh:

Substances:

Year:  2017        PMID: 28547157     DOI: 10.1007/s10863-017-9714-z

Source DB:  PubMed          Journal:  J Bioenerg Biomembr        ISSN: 0145-479X            Impact factor:   2.945


  26 in total

Review 1.  RIP kinases: key decision makers in cell death and innate immunity.

Authors:  F Humphries; S Yang; B Wang; P N Moynagh
Journal:  Cell Death Differ       Date:  2014-08-22       Impact factor: 15.828

Review 2.  Therapeutic roles of heparin anticoagulants in cancer and related disorders.

Authors:  Sarfraz Ahmad; Asif Ahsan Ansari
Journal:  Med Chem       Date:  2011-09       Impact factor: 2.745

Review 3.  Connections between various trigger factors and the RIP1/ RIP3 signaling pathway involved in necroptosis.

Authors:  Yuan-Yuan Zhang; Hao Liu
Journal:  Asian Pac J Cancer Prev       Date:  2013

Review 4.  Nasopharyngeal carcinoma.

Authors:  Melvin L K Chua; Joseph T S Wee; Edwin P Hui; Anthony T C Chan
Journal:  Lancet       Date:  2015-08-28       Impact factor: 79.321

Review 5.  Apoptosis, oncosis, and necrosis. An overview of cell death.

Authors:  G Majno; I Joris
Journal:  Am J Pathol       Date:  1995-01       Impact factor: 4.307

6.  Apoptosis is induced by shikonin through the mitochondrial signaling pathway.

Authors:  Xuxia Tang; Chen Zhang; Jiongzhou Wei; Yuting Fang; Rongxiang Zhao; Jianxin Yu
Journal:  Mol Med Rep       Date:  2016-03-02       Impact factor: 2.952

7.  A novel role for RIP1 kinase in mediating TNFα production.

Authors:  D E Christofferson; Y Li; J Hitomi; W Zhou; C Upperman; H Zhu; S A Gerber; S Gygi; J Yuan
Journal:  Cell Death Dis       Date:  2012-06-14       Impact factor: 8.469

8.  Neoalbaconol induces cell death through necroptosis by regulating RIPK-dependent autocrine TNFα and ROS production.

Authors:  Xinfang Yu; Qipan Deng; Wei Li; Lanbo Xiao; Xiangjian Luo; Xiaolan Liu; Lifang Yang; Songling Peng; Zhihui Ding; Tao Feng; Jian Zhou; Jia Fan; Ann M Bode; Zigang Dong; Jikai Liu; Ya Cao
Journal:  Oncotarget       Date:  2015-02-10

Review 9.  Molecular crosstalk between apoptosis, necroptosis, and survival signaling.

Authors:  Tom Vanden Berghe; William J Kaiser; Mathieu Jm Bertrand; Peter Vandenabeele
Journal:  Mol Cell Oncol       Date:  2015-04-08

10.  The Tumour Response to Induction Chemotherapy has Prognostic Value for Long-Term Survival Outcomes after Intensity-Modulated Radiation Therapy in Nasopharyngeal Carcinoma.

Authors:  Hao Peng; Lei Chen; Yuan Zhang; Wen-Fei Li; Yan-Ping Mao; Xu Liu; Fan Zhang; Rui Guo; Li-Zhi Liu; Li Tian; Ai-Hua Lin; Ying Sun; Jun Ma
Journal:  Sci Rep       Date:  2016-04-21       Impact factor: 4.379

View more
  7 in total

1.  Downregulation of monocarboxylate transporter 1 inhibits the invasion and migration through suppression of the PI3K/Akt signaling pathway in human nasopharyngeal carcinoma cells.

Authors:  Pei Zhang; Jie Ma; Jiao Gao; Fang Liu; Xiaojin Sun; Fang Fang; Surong Zhao; Hao Liu
Journal:  J Bioenerg Biomembr       Date:  2018-06-07       Impact factor: 2.945

2.  Synergy between sublethal doses of shikonin and metformin fully inhibits breast cancer cell migration and reverses epithelial-mesenchymal transition.

Authors:  Abolfazl Rostamian Tabari; Pegah Gavidel; Farzaneh Sabouni; Mossa Gardaneh
Journal:  Mol Biol Rep       Date:  2022-05-07       Impact factor: 2.742

3.  Integration of Transcriptomics and Metabolomics Reveals the Antitumor Mechanism Underlying Shikonin in Colon Cancer.

Authors:  Yang Chen; Yun Gao; Xiaojiao Yi; Jinghui Zhang; Zhongjian Chen; Yongjiang Wu
Journal:  Front Pharmacol       Date:  2020-10-22       Impact factor: 5.810

Review 4.  Natural Products as Inducers of Non-Canonical Cell Death: A Weapon against Cancer.

Authors:  Giulia Greco; Elena Catanzaro; Carmela Fimognari
Journal:  Cancers (Basel)       Date:  2021-01-15       Impact factor: 6.639

5.  Curcumin Targets Both Apoptosis and Necroptosis in Acidity-Tolerant Prostate Carcinoma Cells.

Authors:  Yoon-Jin Lee; Kwan-Sik Park; Sang-Han Lee
Journal:  Biomed Res Int       Date:  2021-05-22       Impact factor: 3.411

6.  Shikonin overcomes drug resistance and induces necroptosis by regulating the miR-92a-1-5p/MLKL axis in chronic myeloid leukemia.

Authors:  Xianbo Huang; Zhenzhen Chen; Fan Ni; Xiujin Ye; Wenbin Qian
Journal:  Aging (Albany NY)       Date:  2020-09-14       Impact factor: 5.682

7.  Osthole induces necroptosis via ROS overproduction in glioma cells.

Authors:  Mengjie Huangfu; Riming Wei; Juan Wang; Jianli Qin; Dan Yu; Xiao Guan; Xumei Li; Minglei Fu; Haiping Liu; Xu Chen
Journal:  FEBS Open Bio       Date:  2021-01-19       Impact factor: 2.792

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.